|1.||Hankinson, Susan E: 38 articles (12/2015 - 09/2002)|
|2.||Bernstein, Leslie: 28 articles (07/2015 - 11/2003)|
|3.||Malone, Kathleen E: 27 articles (07/2015 - 03/2002)|
|4.||Viale, Giuseppe: 25 articles (10/2015 - 05/2002)|
|5.||Sasano, Hironobu: 24 articles (10/2015 - 07/2002)|
|6.||Lanari, Claudia: 24 articles (06/2015 - 01/2002)|
|7.||Goldhirsch, Aron: 22 articles (10/2015 - 03/2003)|
|8.||Lange, Carol A: 22 articles (04/2014 - 01/2003)|
|9.||Hortobagyi, Gabriel N: 21 articles (12/2015 - 10/2002)|
|10.||Ursin, Giske: 21 articles (07/2015 - 11/2003)|
12/01/2004 - "Positive progesterone receptor remained significant for improved disease-free and overall survival (hazard ratios/P=0.666/0.038 and 0.549/0.007, respectively) in multivariate analyses including the standard variables of tumor size, nodal status, treatment, histological grade, and HER-2/neu status. "
01/01/2005 - "These studies indicate that when progesterone receptor levels are maintained, progestin therapy is effective in limiting tumor growth. "
02/01/1990 - "Tissues surrounding the cancer may contain progesterone receptor and produce false-positive results in biochemical assays. "
12/01/1986 - "Patients with stage I and II disease whose tumors contained elevated levels of cytosol progestin receptors had an improved survival over patients with tumors containing low levels of cytosol progestin receptors. "
10/01/2014 - "Oestrogen receptor (ER), progesterone receptor (PR) and HER2/neu status were evaluated by immunohistochemistry (IHC) on 90 CNBs of primary tumors and surgical specimens after NAC (study group); 53 patients without NAC served as control group, and discordance was compared between the two groups. "
|2.||Breast Neoplasms (Breast Cancer)
04/01/1988 - "In stage II breast cancer, progesterone receptor (PgR) content appears to be better than ER content in predicting disease-free and overall survival. "
07/01/2015 - "Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer."
05/15/1994 - "Assay of oestrogen and progesterone receptors, in the cytosol of primary breast cancer provides information on the differentiation and prognosis of the tumour and on the efficacy of endocrine treatment. "
11/01/1984 - "Oestrogen and progesterone receptors and disease-free interval in primary breast cancer."
01/01/2015 - "Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China."
|3.||Neoplasm Metastasis (Metastasis)
08/01/1994 - "By multivariate analysis, c-erbB-2 failed to be an independent prognostic marker for either disease-free period or overall survival, whereas classical histopathological parameters such as presence of lymph node metastases, high number of mitoses, high histological grade (poor differentiation) and absence of progesterone receptors turned out to be of independent prognostic significance."
01/01/2014 - "Various models showed that from covariates in the study, lymph node involvement ratio and being progesterone receptor positive were significant, with an adverse and a beneficial effect on metastasis free survival, respectively. "
12/01/2011 - "The aim of this study was to examine the protein expression patterns of BCL2, HER2, oestrogen (ER) and progesterone receptors (PR) and to evaluate their correlation with survival and other prognostic parameters such as tumour size, histological grade and metastasis. "
12/01/1995 - "In this study, the expression of nm23-H1 and -H2 was not correlated with stage, metastasis, tumour size, myometrial invasion, oestrogen receptor, progesterone receptor or menopause. "
06/01/2015 - "In conclusion, TFF3 expression is associated with response to endocrine therapy, and outperforms oestrogen receptor, progesterone receptor and TFF1 as an independent biomarker, possibly because it mediates the malign effects of oestrogen on invasion and metastasis. "
07/01/2014 - "The existence of the oestrogen receptor-negative (OR(-))/progesterone receptor-positive (PR(+)) phenotype in canine mammary carcinomas (CMCs) is not well understood, although this phenotype was reported consistently in previous studies. "
02/01/2013 - "Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates."
12/01/2012 - "Prevalence of known prognostic factors in female breast carcinoma including oestrogen receptor, progesterone receptor and Her-2/neu status--a study in a tertiary care centre."
06/01/2012 - "The present study was undertaken to assess the reliability of oestrogen and progesterone receptor (ER, PR) status and HER2 as demonstrated by immunochemistry (IHC) on cell blocks from breast carcinoma cases, in comparison with histological sections. "
10/01/2010 - "In this study we examined the associations and prognostic relevance of medullary histological features in a series of 165 invasive carcinomas with a basal-like phenotype: triple-negative (oestrogen receptor, progesterone receptor, HER2) and expressing at least one basal marker (CK5/6, CK14, CK17 or EGFR). "
|5.||Endometrial Neoplasms (Endometrial Cancer)
09/07/2005 - "The prognosis of endometrial carcinoma patients can be improved with adjuvant endocrine therapy, especially for those with positive progesterone receptor. "
06/01/2015 - "To study the effect of total matrines and extracts from Periplaneta americana on negative endometrial cancer cell JEC of progesterone receptors. "
06/01/2015 - "[Study on effect of total matrines and extracts from Periplaneta americana on negative endometrial cancer cell JEC of progesterone receptors]."
01/01/2010 - "To study the roles of Pten and K-ras in endometrial cancer, we generated Pten ablation and oncogenic K-ras mutation in progesterone receptor positive cells (PR(cre/+)Pten(f/f)K-ras(G12D)). "
10/01/2007 - "Recent studies on epigenetic reactivation of the progesterone receptor provide a novel approach for re-sensitization of advanced, PR-negative endometrial cancers to progestational therapy."
|6.||Epidermal Growth Factor Receptor (EGF Receptor)
|7.||Mifepristone (RU 486)
|8.||Progesterone Receptors (Progesterone Receptor)
|9.||Estrogen Receptor alpha
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)